Q-omics provides the consensus-scored NCMAP profile across patient tissues and cancer cell-line models. NCMAP expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, NCMAP is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, NCMAP RNA expression shows 14,879 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, KIRC, and THYM as cancer lineages where NCMAP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCMAP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCMAP survival associations across molecular data types. NCMAP RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCMAP RNA expression–survival associations across cancer types. High NCMAP expression shows unfavorable associations in LUSC and ESCA, but favorable associations in UCEC, SKCM, DLBC and ACC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for NCMAP RNA expression.
This table summarizes NCMAP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NCMAP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCMAP shows lower tumor expression in KIRC, LUAD, LUSC, BRCA and KICH and higher tumor expression in UCEC. The KIRC box plot shows higher NCMAP RNA expression in normal versus tumor tissue (log2 FC = −1.489, t-test p < 0.001).
This table shows molecular features associated with NCMAP in patient tissues and cancer cell lines. In patient samples, NCMAP shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NCMAP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_NSCLC_LUAD.
